JP2023113681A5 - - Google Patents
Info
- Publication number
- JP2023113681A5 JP2023113681A5 JP2023080568A JP2023080568A JP2023113681A5 JP 2023113681 A5 JP2023113681 A5 JP 2023113681A5 JP 2023080568 A JP2023080568 A JP 2023080568A JP 2023080568 A JP2023080568 A JP 2023080568A JP 2023113681 A5 JP2023113681 A5 JP 2023113681A5
- Authority
- JP
- Japan
- Prior art keywords
- methods
- new products
- manufacturing methods
- manufacturing
- methods substantially
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527744P | 2017-06-30 | 2017-06-30 | |
| US62/527,744 | 2017-06-30 | ||
| US201862653436P | 2018-04-05 | 2018-04-05 | |
| US62/653,436 | 2018-04-05 | ||
| US201862673064P | 2018-05-17 | 2018-05-17 | |
| US62/673,064 | 2018-05-17 | ||
| PCT/US2018/040286 WO2019006299A1 (en) | 2017-06-30 | 2018-06-29 | COMPOSITIONS AND METHODS FOR THE USE OF 2- (4-CHLOROPHENYL) -N - ((2- (2,6-DIOXOPIPERIDIN-3-YL) -1-OXOISOINDOLIN-5-YL) METHYL) -2,2-DIFLUOROACETAMIDE |
| JP2019572475A JP2020526501A (ja) | 2017-06-30 | 2018-06-29 | ２−（４−クロロフェニル）−ｎ−｛［２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル］メチル｝−２，２−ジフルオロアセトアミドの組成物及び使用法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572475A Division JP2020526501A (ja) | 2017-06-30 | 2018-06-29 | ２−（４−クロロフェニル）−ｎ−｛［２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル］メチル｝−２，２−ジフルオロアセトアミドの組成物及び使用法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023113681A JP2023113681A (ja) | 2023-08-16 |
| JP2023113681A5 true JP2023113681A5 (https=) | 2026-01-15 |
Family
ID=64741897
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572475A Pending JP2020526501A (ja) | 2017-06-30 | 2018-06-29 | ２−（４−クロロフェニル）−ｎ−｛［２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル］メチル｝−２，２−ジフルオロアセトアミドの組成物及び使用法 |
| JP2023080568A Pending JP2023113681A (ja) | 2017-06-30 | 2023-05-16 | ２－（４－クロロフェニル）－ｎ－｛［２－（２，６－ジオキソピペリジン－３－イル）－１－オキソイソインドリン－５－イル］メチル｝－２，２－ジフルオロアセトアミドの組成物及び使用法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019572475A Pending JP2020526501A (ja) | 2017-06-30 | 2018-06-29 | ２−（４−クロロフェニル）−ｎ−｛［２−（２，６−ジオキソピペリジン−３−イル）−１−オキソイソインドリン−５−イル］メチル｝−２，２−ジフルオロアセトアミドの組成物及び使用法 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20190030018A1 (https=) |
| EP (2) | EP4201399A3 (https=) |
| JP (2) | JP2020526501A (https=) |
| KR (1) | KR20200020899A (https=) |
| CN (1) | CN111032043A (https=) |
| AU (1) | AU2018294327A1 (https=) |
| BR (1) | BR112019028101A2 (https=) |
| CA (1) | CA3068591A1 (https=) |
| CL (1) | CL2019003857A1 (https=) |
| DK (1) | DK3644999T3 (https=) |
| ES (1) | ES2939739T3 (https=) |
| FI (1) | FI3644999T3 (https=) |
| HR (1) | HRP20230210T1 (https=) |
| HU (1) | HUE061356T2 (https=) |
| IL (1) | IL271726A (https=) |
| LT (1) | LT3644999T (https=) |
| MX (2) | MX2019015886A (https=) |
| PL (1) | PL3644999T3 (https=) |
| PT (1) | PT3644999T (https=) |
| RS (1) | RS64029B1 (https=) |
| SG (1) | SG11201913008TA (https=) |
| SI (1) | SI3644999T1 (https=) |
| SM (1) | SMT202300068T1 (https=) |
| WO (1) | WO2019006299A1 (https=) |
| ZA (1) | ZA201908605B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12435128B2 (en) | 2017-05-31 | 2025-10-07 | Taiho Pharmaceutical Co., Ltd. | Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 |
| WO2020146440A1 (en) | 2019-01-09 | 2020-07-16 | Celgene Corporation | Antiproliferative compounds and second active agents for use in treating multiple myeloma |
| BR112021025537A2 (pt) | 2019-06-20 | 2022-03-03 | Celgene Quanticel Res Inc | Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica |
| BR112022007996A2 (pt) * | 2019-10-28 | 2022-07-05 | Celgene Corp | Métodos para o tratamento e uso de biomarcadores para predizer a sensibilidade clínica à 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida |
| KR20220106976A (ko) * | 2019-10-28 | 2022-08-01 | 셀진 코포레이션 | 백혈병을 치료하는 방법, 및 요법에 대한 임상 민감도를 예측하기 위한 백혈병 줄기 세포 시그니처의 용도 |
| MX2022005812A (es) | 2019-11-13 | 2022-08-16 | Taiho Pharmaceutical Co Ltd | Metodos de tratamiento de enfermedades y trastornos relacionados con desmetilasa 1 especifica de lisina con inhibidores de desmetilasa 1 especifica de lisina. |
| EP4121051A4 (en) * | 2020-03-16 | 2024-04-17 | Celgene Corporation | COMBINATION THERAPY FOR ACUTE MYELOID LEUKEMIA |
| CN116583509A (zh) * | 2020-10-07 | 2023-08-11 | 上海睿跃生物科技有限公司 | 治疗癌症的化合物和方法 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| CN113125602A (zh) * | 2021-04-16 | 2021-07-16 | 山东铂源药业有限公司 | 一种哌柏西利中残留溶剂的检测方法 |
| WO2024015855A1 (en) * | 2022-07-13 | 2024-01-18 | Monte Rosa Therapeutics, Inc. | COMBINATION THERAPY COMPRISING GSPT1-DIRECTED MOLECULAR GLUE DEGRADERS AND PI3K/AKT/mTOR PATHWAY INHIBITORS |
| TW202423434A (zh) * | 2022-10-07 | 2024-06-16 | 瑞士商歐庫利斯營運股份有限公司 | mTOR抑制劑的點眼劑微懸液 |
| KR102821060B1 (ko) | 2023-03-09 | 2025-06-16 | 미네암리타 테라퓨틱스, 엘엘씨 | 위암의 치료를 위한 약물 조합 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0011312A1 (en) | 1977-07-09 | 1980-05-28 | LUCAS INDUSTRIES public limited company | Road vehicle electrical systems |
| DE2848746A1 (de) | 1978-11-10 | 1980-05-22 | Wolfgang Arheiliger | Dichtung fuer eine schwellenlose tuere mit drehfluegel |
| DE3346123A1 (de) * | 1983-12-21 | 1985-06-27 | Janssen Pharmaceutica, N.V., Beerse | Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung |
| US5391485A (en) | 1985-08-06 | 1995-02-21 | Immunex Corporation | DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues |
| US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
| JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9126209D0 (en) * | 1991-12-10 | 1992-02-12 | Orion Yhtymae Oy | Drug formulations for parenteral use |
| US5360352A (en) | 1992-12-24 | 1994-11-01 | The Whitaker Corporation | Wire retainer for current mode coupler |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US6051227A (en) | 1995-07-25 | 2000-04-18 | The Regents Of The University Of California, Office Of Technology Transfer | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5855887A (en) | 1995-07-25 | 1999-01-05 | The Regents Of The University Of California | Blockade of lymphocyte down-regulation associated with CTLA-4 signaling |
| US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
| US5948893A (en) | 1996-01-17 | 1999-09-07 | The United States Of America As Represented By The Secretary Of The Navy | Murine hybridoma and antibody binding to CD28 receptor secreted by the hybridoma and method of using the antibody |
| US6207157B1 (en) | 1996-04-23 | 2001-03-27 | The United States Of America As Represented By The Department Of Health And Human Services | Conjugate vaccine for nontypeable Haemophilus influenzae |
| US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
| IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
| US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| WO2003042402A2 (en) | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| US7498171B2 (en) | 2002-04-12 | 2009-03-03 | Anthrogenesis Corporation | Modulation of stem and progenitor cell differentiation, assays, and uses thereof |
| CN1753912B (zh) | 2002-12-23 | 2011-11-02 | 惠氏公司 | 抗pd-1抗体及其用途 |
| RU2494107C2 (ru) | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| CN104356236B (zh) | 2005-07-01 | 2020-07-03 | E.R.施贵宝&圣斯有限责任公司 | 抗程序性死亡配体1(pd-l1)的人单克隆抗体 |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| WO2009114335A2 (en) | 2008-03-12 | 2009-09-17 | Merck & Co., Inc. | Pd-1 binding proteins |
| KR101814408B1 (ko) | 2008-09-26 | 2018-01-04 | 다나-파버 캔서 인스티튜트 인크. | 인간 항-ｐｄ-１, ｐｄ-ｌ１, 및 ｐｄ-ｌ2 항체 및 그의 용도 |
| AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
| WO2010089411A2 (en) | 2009-02-09 | 2010-08-12 | Universite De La Mediterranee | Pd-1 antibodies and pd-l1 antibodies and uses thereof |
| WO2011066342A2 (en) | 2009-11-24 | 2011-06-03 | Amplimmune, Inc. | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011082400A2 (en) | 2010-01-04 | 2011-07-07 | President And Fellows Of Harvard College | Modulators of immunoinhibitory receptor pd-1, and methods of use thereof |
| JP2013532153A (ja) | 2010-06-18 | 2013-08-15 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| NZ627096A (en) | 2012-01-06 | 2017-02-24 | Agios Pharmaceuticals Inc | Triazinyl compounds and their methods of use |
| BR112015002285B1 (pt) * | 2012-08-09 | 2022-05-10 | Celgene Corporation | Uso do composto 3-(4-((4-(morfolinometil)benzil)oxi)-1-oxoisoindolin-2-il)piperidina-2,6-diona para tratar ou gerenciar câncer |
| CN105593215B (zh) | 2013-07-11 | 2019-01-15 | 安吉奥斯医药品有限公司 | 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物 |
| MY185687A (en) | 2013-07-11 | 2021-05-30 | Agios Pharmaceuticals Inc | N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer |
| WO2015003355A2 (en) | 2013-07-11 | 2015-01-15 | Agios Pharmaceuticals, Inc. | Therapeutically active compounds and their methods of use |
| US9579324B2 (en) | 2013-07-11 | 2017-02-28 | Agios Pharmaceuticals, Inc | Therapeutically active compounds and their methods of use |
| TWI666208B (zh) | 2013-08-02 | 2019-07-21 | 美商阿吉斯藥品有限公司 | 治療活性化合物及其使用方法（三） |
| TW201540323A (zh) * | 2014-01-15 | 2015-11-01 | Celgene Corp | ３－（５－胺基－２－甲基－４－側氧基－４ｈ－喹唑啉－３－基）－哌啶－２，６－二酮之調配物 |
| US9499514B2 (en) * | 2014-07-11 | 2016-11-22 | Celgene Corporation | Antiproliferative compounds and methods of use thereof |
| WO2017120437A1 (en) | 2016-01-08 | 2017-07-13 | Celgene Corporation | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide |
| EP3399981B1 (en) | 2016-01-08 | 2023-08-02 | Celgene Corporation | Solid forms of 2-(4-chlorophenyl)-n-((2-2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl) methyl)-2,2-difluoroacetamide, and their pharmaceutical compositions and uses |
-
2018
- 2018-06-29 EP EP22212562.7A patent/EP4201399A3/en not_active Withdrawn
- 2018-06-29 BR BR112019028101-0A patent/BR112019028101A2/pt not_active Application Discontinuation
- 2018-06-29 PT PT188237192T patent/PT3644999T/pt unknown
- 2018-06-29 MX MX2019015886A patent/MX2019015886A/es unknown
- 2018-06-29 SM SM20230068T patent/SMT202300068T1/it unknown
- 2018-06-29 SG SG11201913008TA patent/SG11201913008TA/en unknown
- 2018-06-29 EP EP18823719.2A patent/EP3644999B1/en active Active
- 2018-06-29 JP JP2019572475A patent/JP2020526501A/ja active Pending
- 2018-06-29 ES ES18823719T patent/ES2939739T3/es active Active
- 2018-06-29 HU HUE18823719A patent/HUE061356T2/hu unknown
- 2018-06-29 CN CN201880056213.2A patent/CN111032043A/zh active Pending
- 2018-06-29 PL PL18823719.2T patent/PL3644999T3/pl unknown
- 2018-06-29 US US16/024,581 patent/US20190030018A1/en not_active Abandoned
- 2018-06-29 DK DK18823719.2T patent/DK3644999T3/da active
- 2018-06-29 KR KR1020207002231A patent/KR20200020899A/ko not_active Withdrawn
- 2018-06-29 HR HRP20230210TT patent/HRP20230210T1/hr unknown
- 2018-06-29 SI SI201830859T patent/SI3644999T1/sl unknown
- 2018-06-29 AU AU2018294327A patent/AU2018294327A1/en not_active Abandoned
- 2018-06-29 RS RS20230153A patent/RS64029B1/sr unknown
- 2018-06-29 WO PCT/US2018/040286 patent/WO2019006299A1/en not_active Ceased
- 2018-06-29 LT LTEPPCT/US2018/040286T patent/LT3644999T/lt unknown
- 2018-06-29 CA CA3068591A patent/CA3068591A1/en active Pending
- 2018-06-29 FI FIEP18823719.2T patent/FI3644999T3/fi active
-
2019
- 2019-12-20 MX MX2022001410A patent/MX2022001410A/es unknown
- 2019-12-23 ZA ZA2019/08605A patent/ZA201908605B/en unknown
- 2019-12-26 IL IL271726A patent/IL271726A/en unknown
- 2019-12-26 CL CL2019003857A patent/CL2019003857A1/es unknown
-
2023
- 2023-05-16 JP JP2023080568A patent/JP2023113681A/ja active Pending